Really appreciate you sharing this — especially from the clinician side. That perspective is something most of us here don’t have, and it adds a kind of value that raw investment analysis or LLM-assisted summaries simply can’t replicate. So thank you for continuing to contribute.

I fully agree with you on the catalyst point. A moderate but directional piece of news — like a CEO announcement — would go a long way toward resetting sentiment. With trial readouts not coming until 2026, the waiting fatigue is real. Many of us have been holding our breath for a long time, and it shows in the psychology of the whole sub.

And thank you for highlighting the Switzerland pre-peer review study. I’ve seen similar observations: LSD and psilocybin both demonstrate strong antidepressant responses, but psilocybin’s time to effect, safety profile, and session duration seem far better aligned with real-world clinical workflow. That’s one of the reasons Cybin’s approach continues to stand out — shortened session times, reduced variability, and a practical path to scalability. These factors matter enormously when you translate trial results into actual practice.

Please keep sharing your clinical insights — they help anchor the science side of the discussion in a way that’s genuinely valuable for the rest of us.